Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
Continuing in its quest for the holy grail of a novel HDL cholesterol drug, Resverlogix maintains that an upcoming Phase IIb trial will test a more appropriate, higher-risk population and study patients longer.